Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian S Ray

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|June 4, 2025
Practical perspectives on addressing hepatotoxicity during clinical candidate selectionAdrian S Ray
AIDS Reviews|August 12, 2005
Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptaseAdrian S Ray
The Journal of Infectious Diseases|April 3, 2007
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse eventsAdrian S Ray, Tomas Cihlar
Antiviral Research|November 6, 2009
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudineTomas Cihlar, Adrian S Ray
The Enzymes|October 26, 2021
HCV RdRp, sofosbuvir and beyondJoy Y Feng, Adrian S Ray
Antiviral Research|September 1, 2011
Application of kinase bypass strategies to nucleoside antiviralsAdrian S Ray, Karl Y Hostetler
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2017
Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxinsEve-Irene Lepist, Adrian S Ray
Journal of Clinical Pharmacology|July 8, 2016
Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant?Eve-Irene Lepist, Adrian S Ray
Expert Opinion on Drug Metabolism & Toxicology|March 1, 2012
Renal drug-drug interactions: what we have learned and where we are goingEve-Irene Lepist, Adrian S Ray
Antimicrobial Agents and Chemotherapy|March 30, 2004
Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovirAdrian S Ray, Loren Olson, Arnold Fridland
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Expert Opinion on Drug Metabolism & Toxicology|June 4, 2025
Practical perspectives on addressing hepatotoxicity during clinical candidate selectionAdrian S Ray
AIDS Reviews|August 12, 2005
Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptaseAdrian S Ray
The Journal of Infectious Diseases|April 3, 2007
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse eventsAdrian S Ray, Tomas Cihlar
Antiviral Research|November 6, 2009
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudineTomas Cihlar, Adrian S Ray
The Enzymes|October 26, 2021
HCV RdRp, sofosbuvir and beyondJoy Y Feng, Adrian S Ray
Antiviral Research|September 1, 2011
Application of kinase bypass strategies to nucleoside antiviralsAdrian S Ray, Karl Y Hostetler
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2017
Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxinsEve-Irene Lepist, Adrian S Ray
Journal of Clinical Pharmacology|July 8, 2016
Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant?Eve-Irene Lepist, Adrian S Ray
Expert Opinion on Drug Metabolism & Toxicology|March 1, 2012
Renal drug-drug interactions: what we have learned and where we are goingEve-Irene Lepist, Adrian S Ray
Antimicrobial Agents and Chemotherapy|March 30, 2004
Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovirAdrian S Ray, Loren Olson, Arnold Fridland
Pageof 11